Regenerative Dermatology
The science of growing back.
Flourish Biologics is advancing a first-in-class regenerative therapy that reactivates the body’s own hair-growth cycle at its source’ for the nearly 100 million Americans living with non-scarring hair loss.
WHY FLOURISH
A fundamentally new mechanism for hair loss.
Today’s treatments manage symptoms at the margins. Our approach works upstream, at the receptor that controls the hair-growth cycle itself.
First-in-class
A patent-protected hair-cycle stimulator with a novel mechanism, not another reformulation of a 30-year-old drug.
Regenerative
Activating the PTH receptor restarts follicle morphogenesis, regrowing hair rather than slowing its loss.
Durable & de-risked
Designed for a single injection every one to six months, supported by preclinical efficacy and an FDA-aligned path.
- - THE OPPORTUNITY
A $30B market,
substantially de-risked.
Flourish Biologics is a therapeutic company built on parathyroid-hormone-receptor–mediated treatment of androgenetic alopecia and other forms of hair loss. Our lead molecule, BMD-1171, pairs a hair-growth signal with a collagen-anchoring domain for a targeted, sustained effect.
- Patent-protected, first-in-class hair-cycle stimulators for alopecia of various causes.
- Efficacy demonstrated in preclinical animal studies and an exploratory proof-of-principle human study.
- FDA INTERACT meeting (Q3 2025) confirms the development approach.
$30B
Addressable
U.S. market
~100M
Americans with
non-scarring alopecia
1-6
Months between
doses (target)
3
Major alopecia
markets addressed
THE MARKETS
One molecule, three major markets.
Flourish’s regenerative approach addresses all three major non-scarring alopecia markets, a combined U.S. opportunity north of $30 billion.
Lead indication
Androgenetic Alopecia
>$20B
Male and female pattern hair loss, roughly 80 million Americans, with no durable, effective standard of care.
Initial clinical focus
Alopecia Areata
~$4B
An autoimmune cause of hair loss with a known FDA pathway, and a need for non-immunosuppressant options.
Expansion
Chemo-Induced
~$6B
Over half of patients call this the most traumatic part of chemotherapy, and current options are limited.
A first-in-class regenerative therapy for androgenetic alopecia and other forms of hair loss — building quality of life.
© 2026 Flourish Biologics
This website is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Forward-looking statements regarding the company’s research and development are subject to risks and uncertainties.